Brief: Sino Biopharmaceutical Enters Exclusive License Agreement With Astrazeneca For TQC3721
07/07/2026 23:08
BRIEF-Sino Biopharmaceutical Enters Exclusive License Agreement With Astrazeneca For TQC3721 July 8 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK:
ENTERS EXCLUSIVE LICENSE AGREEMENT WITH ASTRAZENECA FOR TQC3721
ASTRAZENECA GRANTED EXCLUSIVE RIGHTS TO TQC3721 OUTSIDE CHINA
ELIGIBLE FOR $200 MILLION UPFRONT, MILESTONES UP TO $1.9 BILLION, AND TIERED ROYALTIES
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit